ITIH4抗体;ITIH4 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P13655(ITIH4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13655(ITIH4 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ITIH4 antibody targets inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), a glycoprotein encoded by the *ITIH4* gene. ITIH4 is part of the inter-alpha-trypsin inhibitor (ITI) family, which stabilizes the extracellular matrix by covalently binding hyaluronan and other glycosaminoglycans. Primarily synthesized in the liver, ITIH4 acts as an acute-phase protein, upregulated during inflammation or tissue injury. It plays roles in innate immunity, cell adhesion, and inflammation regulation.

ITIH4 is proteolytically processed to release bioactive fragments, such as the C-terminal peptide (SHE78-ITIH4), which has been studied as a potential biomarker in cancers (e.g., ovarian, colorectal) and cardiovascular diseases. Dysregulated ITIH4 expression correlates with tumor progression, metastasis, and immune modulation.

Antibodies against ITIH4 are essential tools for detecting its expression, localization, and post-translational modifications in research. They are used in techniques like Western blotting, immunohistochemistry, and ELISA to investigate ITIH4’s physiological and pathological roles. Clinically, ITIH4 antibodies may aid in diagnosing diseases or monitoring therapeutic responses. However, cross-reactivity with other ITIH family members requires careful validation to ensure specificity. Research continues to explore ITIH4’s dual roles in inflammation and cancer, highlighting its therapeutic potential.